Publication Name	World Journal of Hepatology
Manuscript ID	7282
Country	Italy

Received	2013-11-12 14:56
Peer-Review Started	2013-11-13 12:07
To Make the First Decision	2013-11-19 12:49
Return for Revision	2013-11-19 14:22
Revised	2014-01-07 03:06
Second Decision	2014-03-17 14:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-03-17 14:50
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-03-21 02:45
Typeset the Manuscript	2014-05-17 21:43
Publish the Manuscript Online	2014-05-27 11:34

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Genetics & Heredity
Manuscript Type	Review
Article Title	Chronic hepatitis B: advances in treatment
Manuscript Source	Invited Manuscript
All Author List	Teresa Antonia Santantonio and Massimo Fasano
Funding Agency and Grant Number
Corresponding Author	Dr. Teresa Antonia Santantonio, Department of Clinical and Experimental Medicine, University of Foggia, Ospedali Riuniti, Viale Luigi Pinto 1, 71100 Foggia, Italy. teresa.santantonio@unifg.it
Key Words	Chronic hepatitis; Antiviral therapy; Peg-interferon; Nucleos(t)ide analogues; Antiviral resistance
Core Tip	Patients with chronic hepatitis B are a heterogeneous population and require different management strategies. In clinical practice, several baseline factors, related to the patient, drug, stage of liver disease, comorbidities, lifestyle factors, coinfections and profile of hepatitis B virus infection, should be taken into consideration in order to individually optimize therapy. Surface antigen of the hepatitis B virus quantification is a potential new biomarker for treatment individualization and response-guided therapy. In the last two decades, the availability of potent oral antivirals changed the natural history of chronic hepatitis B; however, the risk of hepatocellular carcinoma (HCC) has not been abolished and thus regular HCC surveillance in high risk patients is required.
Publish Date	2014-05-27 11:34
Citation	Santantonio TA, Fasano M. Chronic hepatitis B: advances in treatment. World J Hepatol 2014; 6(5): 284-292
URL	http://www.wjgnet.com/1948-5182/full/v6/i5/284.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i5.284

Full Article (PDF)	WJH-6-284.pdf
Full Article (Word)	WJH-6-284.doc
Manuscript File	7282-Review.doc
Answering Reviewers	7282-Answering reviewers.pdf
Copyright License Agreement	7282-Copyright assignment.pdf
Peer-review Report	7282-Peer reviews.pdf
Scientific Editor Work List	7282-Scientific editor work list.doc